Bone metastases represent a critical manifestation of advanced cancer, characterized by the dissemination of cancer cells from a primary tumor to bone tissue, where they disrupt normal bone remodeling processes with subsequent skeletal complications such as pain, fractures, and spinal cord compression. Management of bone metastases requires a multifaceted approach to alleviate symptoms and preserve quality of life. Oligometastasis, defined by limited metastatic lesions confined to one or a few organs, presents a unique therapeutic opportunity. This state reflects a lower tumor burden and slower tumor kinetics, potentially amenable to curative-intent treatments such as surgical resection, stereotactic body radiation therapy (SBRT), or ablative therapies. Molecular characterization reveals distinct profiles in oligometastatic lesions, influencing treatment decisions and offering insights into targeted therapeutic strategies. This abstract highlights the clinical challenges and therapeutic advancements in managing bone metastases, emphasizing the evolving understanding of oligometastasis as a distinct clinical entity with implications for personalized oncological care.